Postpartum depression is a mood disorder in women associated with the child birth. The birth of a child can trigger varying degree of emotions, from excitement to joy to anxiety and fear. But it can also result in to depression called as postpartum depression. Postpartum depression is caused by a combination of factors both physical and emotional. After childbirth fluctuation in the level of hormones in women’s body take place.
This fluctuation in the hormone level leads to chemical change triggering the mood swings. Other factors causing the postpartum depression includes constant sleep deprivation but this condition is treated after proper rest. But in some cases women experience more severe depression and require medications. Symptoms of postpartum depression includes, sadness, inability to care for baby, crying, trouble in bonding to baby, lack of focus and troubled with memory.
Get Sample Copy of this Report @ https://www.persistencemarketresearch.com/samples/17656
Market Segmentation:
On the basis of Drug Class
- Selective Serotonin Reuptake Inhibitors
- Serotonin Norepinephrine Reuptake Inhibitors
- Tricyclic Antidepressants
- Monoamine Oxidase Inhibitors
On the basis of Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
The postpartum depression therapeutics market is expected to show significant growth over the period owning to increasing prevalence owing to changing lifestyle and trend to a nuclear family which might leave new mother a the risk of depression.
For the entire list of market players, request for Table of Content here @ https://www.persistencemarketresearch.com/toc/17656
Geographically, the global postpartum depression therapeutic market can be segmented into regions: North America, Latin America, Europe, Asia Pacific and Middle East & Africa. North America dominates the postpartum depression therapeutic market owning to high consumption of the antidepressants in the U.S., branded drugs and intense lifestyle.
Europe is second biggest market for the postpartum depression therapeutics market. North America and Europe are expected to continue to do dominate the market due to increasing awareness among people regarding the postpartum depression, better healthcare facilities and programs by various government and non-government organization to ensure the safety of mother and child.
Pre-Book Right Now for Exclusive Analyst Support @ https://www.persistencemarketresearch.com/checkout/17656
Some of the market participants in the global postpartum depression therapeutics involves, Pfizer, Inc., Allegan, Eli Lilly Company, H. Lundbeck A/S, GlaxoSmithKline plc, Solvay S.A., AstraZeneca plc, Novartis AG and Sage Therapeutics, Inc. Major focus of the companies is on the development of the specific medication for the postpartum depression and companies are using the awareness campaigns to increase their shares in the postpartum depression therapeutics market.
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007, United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com